$PHIO

Best Value Stocks to Buy for May 28th

PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.

Original reporting
Zacks Commentary · Zacks Equity Research
Published May 28, 2025, 1:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2025, 12:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Best Value Stocks to Buy for May 28th — source image
Decision brief

The 30-second read

$PHIOBullishMed
01

Why it matters

The positive rankings and sentiment suggest a bullish outlook, potentially attracting short-term trading activity.

02

Market read

The stocks are relevant within their respective sectors, with potential to influence sector ETFs and indices if positive momentum sustains.

03

What to watch

Potential macroeconomic shifts, interest rate changes, or sector-specific challenges could impact these stocks' performance despite positive sentiment.

Timing: Immediate to short-term (next 4 weeks)

Background

The article highlights stocks with the highest Zacks Rank #1 (Strong Buy) status as of May 28, 2025, indicating strong analyst confidence and favorable valuation metrics.

Company-level read

Ticker impact

$PHIOBullishHigh confidence
Context

High relevance due to strong buy rating and positive sentiment.

Expected impact

Expected moderate increase of 5-10% over the next 4 weeks.

Evidence & confidence

The stock's ranking as a Zacks Rank #1 and favorable sentiment suggest strong upward momentum, supported by positive earnings outlooks.

$ALRSBullishMedium confidence
Context

Moderate relevance; positive sentiment but slightly lower impact due to industry volatility.

Expected impact

Potential increase of 3-7% over the next month.

Evidence & confidence

While the stock shows positive indicators, industry-specific risks may temper gains.

$URBNBullishMedium confidence
Context

Moderate relevance; positive sentiment but industry-specific factors could influence performance.

Expected impact

Expected rise of 2-5% in the upcoming month.

Evidence & confidence

The positive sentiment supports gains, but sector trends and consumer spending patterns could affect outcomes.

Market effects

Potential positive impact on Life Sciences, Retail & Wholesale, and Financial Markets sectors due to increased investor interest in value stocks.

Limited regional impact; primarily US-focused stocks.

Minimal direct relevance; localized to specific sectors and stocks.

Counterpoint

Some analysts may view the strong buy ratings as overly optimistic, citing potential overvaluation or upcoming sector headwinds.

Key entities

  • PHIO

    Phio Pharmaceuticals Corp., involved in immunotherapy research.

  • ALRS

    Alerus Financial Corporation, a financial services company.

  • URBN

    Urban Outfitters Inc., a retailer in lifestyle and apparel.

Related articles

$PHIOMedAI 8/10

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

$PHIOMed

Phio Pharmaceuticals Corp. (PHIO): Results of Operations and Financial Condition

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_965504.htm EXHIBIT 99.1 ex_965504.htm Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical to

$URBNMedAI 8/10

Urban Company Reports Q1 FY27 Results: Operational Revenue Surges 43.8% to ₹528.34 Crore as Consolidated Net Loss Narrows

Urban Company Limited reported unaudited Q1 FY27 (ended June 30, 2026) results. Consolidated revenue from operations rose 43.86% YoY to ₹528.34 crore, with consolidated net loss narrowing to ₹92.12 crore. Consolidated expenses were ₹639.88 crore. Segment revenue grew across India Consumer Services, Native, and International, while InstaHelp remained loss-making. Shares last traded at Rs. 129.35 on BSE.

$ALRSMed

ALERUS FINANCIAL CORP (ALRS): Results of Operations and Financial Condition

ALERUS FINANCIAL CORP (ALRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_955234.htm EXHIBIT 99.1 ex_955234.htm Exhibit 99.1 Alan A. Villalon, Chief Financial Officer 952.417.3733 (Office) FOR RELEASE (7.29.2026) ALERUS FINANCIAL CORPORATION REPORTS Second QUARTER 2026 NET INCOME OF $20.9 MILLION MINNEAPOLIS, MN ( July 29, 2026 ) – Alerus

$URBNMedAI 9/10

Urban Outfitters Stock Stalls Despite Another Strong Quarter

Urban Outfitters said it is off to a solid start in Q2 and expects high-single-digit sales growth for both Q2 and the full fiscal year, according to CFO Melanie Marein-Efron. It warned Q2 gross margins may be flat to down ~25 bps from lower IMU, tariffs, and fuel surcharges, though full-year margins could rise ~25 bps. Shares at $71.36 were near pre-earnings; analysts’ consensus target is just over $87.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.